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ABSTRACT
Objective: To evaluate the gene expression of beta-trace protein in 
urine of diabetic patients, with no reduction in glomerular filtration 
rate, which was defined as below 60mL/min/1.73m2. Methods: 
Type 2 diabetes mellitus patients were recruited, and a group of 
non-diabetic individuals served as control. Beta-trace protein gene 
expression was analyzed by quantitative PCR. Blood samples were 
collected to establish glucose levels and baseline kidney function. 
Accuracy was analyzed using ROC curves. Results: Ninety type 
2 diabetes mellitus patients and 20 non-diabetic individuals were 
recruited. The area under the curve was 0.601, sensitivity of 20% 
and specificity of 89.47%. Among diabetic participants, 18% showed 
an expression above the cutoff point. Conclusion: These results of 
accuracy of beta-trace protein gene expression in urine of diabetic 
patients are promising, although they did not achieve a higher area 
under the curve level.
Keywords: Beta-trace protein; Prostaglandins D/biosynthesis; Diabetes 
mellitus, type 2; Gene expression; Biomarkers/urine
RESUMO
Objetivo: Avaliar a expressão do gene da proteína beta-traço na urina 
de pacientes diabéticos, sem redução na taxa de filtração glomerular, 
definida como abaixo de 60mL/min/1,73m2. Métodos: Foram recrutados 
pacientes com diabetes mellitus tipo 2, e um grupo de indivíduos não 
diabéticos serviu como controle. A expressão do gene da proteína 
beta-traço foi analisada por PCR quantitativa. Amostras de sangue 
foram coletadas para estabelecer níveis de glicemia e função renal 
inicial. A acurácia foi analisada utilizando curvas ROC. Resultados: 
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Foram recrutados 90 pacientes com diabetes mellitus tipo 2 e 20 não 
diabéticos. A área sob a curva foi de 0,601, com sensibilidade de 20% 
e especificidade de 89,47%. Entre os diabéticos, 18% apresentaram 
expressão acima do ponto de corte. Conclusão: Estes resultados de 
acurácia da expressão do gene da proteína beta-traço na urina de 
pacientes diabéticos são promissores, apesar de não terem atingido 
um nível alto na área sob a curva.
Descritores: Proteína beta-traço; Prostaglandinas D/biossíntese; 
Diabetes mellitus tipo 2; Expressão gênica; Biomarcadores/urina
INTRODUCTION
Prostaglandin D-synthase, also known as lipocalin-type 
beta-trace protein (BTP), is a low-molecular-weight 
protein of 168 amino acids, encoded on chromosome 
9. Beta-trace protein is widely present in a variety of 
tissues and body fluids. The molecular weight of BTP 
varies among its different isoforms, ranging from 23 to 
29kDa. These isoforms are produced through a post-
translational process of N-glycosylation, with the lower-
weight isoforms being found mainly in cerebrospinal 
fluid, and those of higher molecular weight in the blood 
and urine.(1,2)
The two main serum measurements used in the 
diagnosis of diabetes are blood glucose and the glycated 
hemoglobin. As with other chronic diseases, the search 
for more sensitive and specific biomarkers of diabetes is 
important to enable earlier interventions, to minimize 
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Urinary BTP gene expression was measured by 
isolating urinary RNA (1μg, initially), which was then 
converted into first-strand cDNA with the aid of 
SSIII First Strand qPCR Supermix (Invitrogen, catalog 
number 11,752,050), according to the manufacturer’s 
protocol.
The expression of the specific BTP gene was 
assessed by quantitative real-time polymerase chain 
reaction (RT-qPCR). To standardize and determine the 
relative expression of the target gene, the reference gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was also expressed. The specific primers of the target 
and reference genes were designed with the help of the 
software Primer3 Input 0.4.0 and were checked for their 
specificity by the Primer-BLAST program. 
For RT-qPCR, an Applied Biosystems 7500 Real 
Time PCR Systems (Applied Biosystems, Foster City, 
USA) thermal cycler was used. Each sample had a 
final volume of 15μL, containing 1 x SYBR Green mix 
(Quantitec SYBR Green PCR kit, QIAGEN Catalog 
no. 204 054), 10pmol of each specific primer and 2μL 
of 10x-diluted cDNA. The parameters of amplification 
included an initial hot start at 95°C for 15 seconds, and 
60°C for the primer sequence.
To verify differences in urinary beta-trace protein 
gene expression between groups, the mean and standard 
deviation were analyzed using the Student’s t test for 
independent samples. The median and first and third 
quartiles were analyzed using the Mann-Whitney test. 
To verify the expression of urinary BTP gene above 
and below the cutoff point of 6.34, as established in 
the literature, the relative frequency was used. The 
verification of a possible association between the 
quantities expressed between the two groups was 
performed using the χ² test.
To determine the sensitivity and specificity of 
BTP as a predictor of diabetes, a receiver operating 
characteristic (ROC) curve was used. The chance of 
positive or negative results in diabetic patients based upon 
the expression of BTP was evaluated, respectively, by 
positive and negative likelihood ratios. The significance 
level was 95%. Statistical analyses were performed using 
Stata software version 11.0® (USA).
This study was approved by the Research Ethics 
Committee of the Faculdade de Medicina do ABC, 
under number 295.177, CAAE: 16235413.0.0000.0082.
RESULTS
A total of 110 patients were recruited for this study: 90 
subjects with T2DM and 20 without diabetes serving as 
the progression of the disease and its complications in 
potential target organs, such as kidneys, heart and brain.
One of the challenges in discovering new biomarkers 
lies in dosing, which should be simple and practical to 
facilitate its clinical use, but can potentially interfere 
in the determination of quantities of the biomarker. 
This is especially true in the case of BTP, given that 
the concentration of BTP is high in sites that are 
undergoing inflammatory processes or, in the case of 
the brain, suffering from trauma. As such, studies of 
BTP as a potential marker of renal dysfunction have 
focused on cases in which elevated levels of BTP have 
been found in blood and urine. In cases in which high 
levels of urinary BTP are verified, it is reasonable to 
consider the possibility kidney damage.(3) As a predictor 
of early renal dysfunction, urinary BTP levels showed 
a better predictive value for kidney disease than other 
traditional biomarkers.(4) 
OBJECTIVE
To evaluate the expression of beta-trace protein gene in 
the urine of patients with diabetes, who do not present 
reduction in glomerular filtration rate, defined as below 
60mL/min/1.73m2.
METHODS
Patients diagnosed with type 2 diabetes mellitus (T2DM) 
with a history of at least 5 years of disease determined in 
accordance with the criteria established by the American 
Diabetes Association were recruited between 2013 and 
2014 among nephrology and endocrinology outpatients 
in the metropolitan area of São Paulo. The exclusion 
criteria included the existence of infection, an active 
malignant neoplasm at the moment of enrolment, 
presence of acquired immunodeficiency syndrome, 
and a diagnosis of end-stage renal disease, under 
conservative treatment or dialysis.
This cross-sectional study was designed to evaluate 
the expression of BTP during diabetes, and did 
not involve changes in the treatment regimen of the 
participants. The two groups studied were classified by 
the presence or absence of T2DM. 
The inclusion criteria for the Control Group were 
absence of diagnosis of diabetes and chronic kidney 
disease, and no family history of diabetes and chronic 
kidney disease.
Samples of blood and urine were collected at the 
time of recruitment to analyze levels of fasting blood 
glucose, glycated hemoglobin, serum creatinine and 
urinary BTP.
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the Control Group. The purpose of the control group 
was to validate the analysis of BTP gene expression.
The Diabetic Group had mean glycated hemoglobin 
of 8.38% and mean eGFR of 79.1mL/min/1.73m2. Of 
the 90 patients, 48.8% were men and the mean age was 
61.3 years. Of the 20 patients in the Control Group, 
25% were men and the total mean age was 38.3 years.
Table 1 shows the mean and median expression 
of BTP observed. Both mean (p=0.08) and median 
(p=0.70) were higher for the Diabetic Group, compared 
to the Control Group, but no statistically significant 
difference between groups was encountered.
expression of the gene for BTP was measured. A 
possible relationship between the presence or absence 
of change in renal function in diabetics and the 
expression of BTP was verified.(5,6) 
Beta-trace protein is widely found in tissues and 
body fluids, and increases in the concentration of BTP 
have been studied as a possible biomarker of reduced 
glomerular filtration rate. However, as with other 
markers, the concentration of BTP found showed great 
variability depending on the method of measurement 
used, in addition to intra-individual fluctuations. Selvin 
et al.,(7) evaluated the coefficient of variation among 
the various markers of glomerular filtration rate, such 
as cystatin C, beta-2 microglobulin and BTP. Of all the 
markers assessed, BTP, when measured in terms of mass 
and concentration, showed the greatest intra-individual 
variability.
This variability is at least partially caused by the 
existence of various isomers of BTP. The discrepant 
measurements are the result of changing relative 
concentrations of each isomer. Furthermore, the 
differences present in side-chain glycosylation, as 
well as differences in clearance, are dependent upon 
the specific fluid (blood, urine or cerebrospinal fluid) 
where the BTP is encountered.(8,9) Beta-trace protein in 
cerebrospinal fluid, with relatively low glycosylation, 
is excreted by the liver, where the isomers with high 
glycosylation rates undergo renal excretion.(8) The 
measurement of BTP based on gene expression, rather 
than on concentration, eliminates variations related to 
isomers.
Given this methodological advantage, the analysis 
of the ROC curve showed satisfactory results, taking 
into account that the value of 0.7 is generally considered 
as the lower limit for a good marker, and above 0.9 is 
considered to be excellent. The fact that this analysis, using 
gene expression, reached a value of 0.61, is promising.
Several studies have verified an increase in 
the concentration of BTP in diabetic patients who 
had already presented other signs of reduced renal 
function.(10,11) An increase in BTP was also verified in 
patients with metabolic syndrome and patients who 
have presented cardiovascular events, suggesting that 
BTP may also be used as a predictor of diabetes.(12) 
However, none of these studies correlated the presence 
of diabetes in the absence of kidney disease or other 
pathological conditions, such as infections or changes 
in cerebrospinal fluid, with increases in BTP. 
CONCLUSION
Urinary beta-trace protein gene expression in diabetic 
patients had good sensitivity and specificity. These 
Table 1. Beta-trace protein expression analysis between groups
Group Mean (SD) CV Median (p.25;p.75) p value* p value
†
Control 1.07 (5.27) 4.93 2.01 (-2.66; 4.15) 0.158 0.080
T2DM 3.57 (5.21) 1.46 2.80 (0.13; 5.42)
* Student’s t test; † Mann-Whitney’s test. SD: standard deviation; CV: coefficient of variation; p.25-p.75: 25 and 75% 
percentile; T2DM: type 2 diabetes mellitus.
Figure 1 shows the diagnostic capacity of BTP as 
a predictor of kidney damage in people with diabetes, 
using the ROC curve. Near the cut-off point established 
by the literature (6.34), BTP as a predictor of kidney 
damage had a sensitivity of 20%, a specificity of 89.47%, 
an accuracy of 39.13%, a positive likelihood ratio of 
1.90 and a negative likelihood ratio of 0.89, with an area 
under the curve (AUC) ROC curve of 0.610. 
Figure 1. Receiver Operating Characteristic curve of urinary beta-trace protein 
gene expression between patients with and without type 2 diabetes mellitus
DISCUSSION
The methodology used in this study is unprecedented 
in the literature because instead of investigating 
the concentration of BTP, the variation based upon 
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results are promising, despite their not having achieved 
a higher area under the curve level.
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